Owing to the overall poor medical health of patients with end-stage renal disease, we have sought alternatives to the use of general anesthesia for access procedures. Furthermore, since local ...
Please provide your email address to receive an email when new articles are posted on . Using regional anesthesia for patients undergoing arteriovenous fistula creation for dialysis access conferred ...
Please provide your email address to receive an email when new articles are posted on . Proteon Therapeutics Inc. has started its second phase 3 study of vonapanitase in patients with chronic kidney ...
Current guidelines advocate the use of native radiocephalic arteriovenous fistulas (AVFs) for vascular access in hemodialysis patients; however, early failure is common in such fistulas. The factors ...
Encouraging Data Indicate Catheter-Based Administration of Vonapanitase Was Generally Well-Tolerated and Technically WALTHAM, Mass., Aug. 13, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc., a ...
WALTHAM, Mass., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Proteon Therapeutics Inc. (Nasdaq:PRTO), a company developing novel, first-in-class therapeutics to address the medical needs of patients with kidney ...
An arteriovenous fistula (AVF) is an abnormal joining of an artery and a vein. If an AVF is affecting health, early treatment can help prevent complications. An AVF occurs if an artery connects to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results